Early initiation of moderate-intensity aerobic exercise during aromatase inhibitor use reduced pain and prevented pain increases among postmenopausal women with breast cancer. Early initiation of ...

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Optimal lead follicle size of 19 to 23 mm was associated with improved clinical pregnancy rates among patients undergoing IUI.

It is administered orally and is prescribed in combination with an aromatase inhibitor as an initial endocrine-based therapy. Additionally, the drug is being developed for the treatment of ...

In the case of breast cancer, women with a higher BMI do have higher rates of recurrence compared to women in the "normal" range.

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

Q4 2024 Earnings Call Transcript March 31, 2025 Celcuity Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, ...

Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen ...